Rua Bioscience Limited (NZE:RUA)
New Zealand · Delayed Price · Currency is NZD 0.0270
-0.0010 (-3.57%)
Oct 2, 2026, 3:31 PM NZST
Rua Bioscience Income Statement
Financials in millions NZD. Fiscal year is July - June.
Millions NZD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Revenue | 2.58 | 1.51 | 0.09 | 0.36 | 0.02 |
Other Revenue | 0.23 | 0.32 | 0.23 | 0.31 | 0.62 |
| 2.81 | 1.83 | 0.32 | 0.67 | 0.65 | |
Revenue Growth | 53.88% | 477.39% | -52.68% | 3.63% | 79.53% |
Cost of Revenue | 1.76 | 0.98 | 0.2 | 0.34 | 0.13 |
Gross Profit | 1.05 | 0.85 | 0.11 | 0.33 | 0.52 |
Research & Development | 0.88 | 0.94 | 1.18 | 1.59 | 2.98 |
Other Operating Expenses | 3.31 | 3.24 | 3.55 | 5.18 | 5.12 |
Operating Expenses | 4.19 | 4.18 | 4.73 | 6.77 | 8.1 |
Operating Income | -3.14 | -3.33 | -4.62 | -6.44 | -7.58 |
Interest Expense | -0.32 | -0.16 | -0.02 | -0.02 | -0.04 |
Interest & Investment Income | 0.03 | 0 | 0.13 | 0.2 | 0.14 |
Currency Exchange Gain (Loss) | 0.09 | - | 0 | - | - |
EBT Excluding Unusual Items | -3.34 | -3.49 | -4.51 | -6.25 | -7.49 |
Impairment of Goodwill | - | - | -8.25 | - | - |
Gain (Loss) on Sale of Assets | -0.02 | 0.03 | -0.53 | - | 0 |
Asset Writedown | - | - | -0.43 | -5.57 | - |
Other Unusual Items | - | 0 | - | 5.86 | - |
Pretax Income | -3.36 | -3.46 | -13.72 | -5.96 | -7.49 |
Income Tax Expense | - | - | - | 0 | 1.15 |
Net Income | -3.36 | -3.46 | -13.72 | -5.96 | -8.64 |
Net Income to Common | -3.36 | -3.46 | -13.72 | -5.96 | -8.64 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 291 | 195 | 158 | 154 | 144 |
Shares Outstanding (Diluted) | 291 | 195 | 158 | 154 | 144 |
Shares Change | 49.23% | 23.01% | 2.95% | 6.63% | 13.17% |
EPS (Basic) | -0.01 | -0.02 | -0.09 | -0.04 | -0.06 |
EPS (Diluted) | -0.01 | -0.02 | -0.09 | -0.04 | -0.06 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -2.96 | -2.79 | -3.74 | -5.99 | -7.25 |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.02 | -0.04 | -0.05 |
Gross Margin | 37.36% | 46.54% | 35.47% | 49.21% | 80.06% |
Operating Margin | -111.65% | -182.57% | -1459.98% | -962.92% | -1175.69% |
Profit Margin | -119.53% | -189.19% | -4336.57% | -891.46% | -1338.73% |
Free Cash Flow Margin | -105.44% | -152.79% | -1181.50% | -896.65% | -1123.09% |
EBITDA | -2.74 | -3 | -4.28 | -5.85 | -6.94 |
EBITDA Margin | -97.54% | -164.01% | - | - | - |
D&A For EBITDA | 0.4 | 0.34 | 0.34 | 0.58 | 0.64 |
EBIT | -3.14 | -3.33 | -4.62 | -6.44 | -7.58 |
EBIT Margin | -111.65% | -182.57% | - | - | - |
Revenue as Reported | 2.9 | 1.9 | 0.32 | 6.53 | 0.65 |